Thai Cannabis to Australia: The Starting-Material Pathway Under TGO 93
UPDATED: JULY 20, 2026
Getting Thai medical cannabis flower into Australia is legal, but it does not work the way the German or EU chain works. Australia does not accept Thai-manufactured finished product, and it does not let unapproved finished cannabis be wholesaled to patients. The route that does work is the starting-material pathway: bulk GACP flower moves as an input for downstream GMP manufacture, not as a patient-ready product. This guide sets out how that pathway works under Australia’s rules, who the buyer is, and where a Thai GACP farm like Solar Farm fits.
This is general information for licensed businesses, not legal or regulatory advice. Import, manufacture and supply decisions in Australia sit with the Therapeutic Goods Administration (TGA), the Office of Drug Control (ODC) and the licensed Australian sponsor or manufacturer.
Finished-Product Wholesale Is Closed: Starting-Material Supply Is Open
If you have read our Thailand-to-Germany export guide, adjust the mental model. Two Australian rules decide the shape of the deal.
First, most medicinal cannabis in Australia is unapproved, not entered on the Australian Register of Therapeutic Goods (ARTG). For finished, patient-ready unapproved product, the TGA prohibits supply through wholesale arrangements; this holds even where the supply is to or by a wholesaler licensed under state or territory law, and the product must stay under the Australian sponsor’s direct control until it reaches a patient through an approved access pathway. So there is no finished-product wholesale market to sell into. (The exception is the small number of ARTG-registered cannabis medicines, such as nabiximols and cannabidiol products, which can be wholesaled in the ordinary way: a separate, registered-product story, not the bulk-flower one.)
Second, and this is the opening, that direct-control rule does not apply to starting materials such as bulk dried flower. Starting material can be supplied through wholesale, on one important condition: material that does not carry accepted GMP evidence may move only to a storage facility and on to a TGA-licensed (or accepted-origin overseas GMP) manufacturing site, not directly to an unlicensed compounding pharmacy or a patient. In other words, the wholesale that is open to a Thai GACP farm is the wholesale of an input into the manufacturing chain, not of a finished dose.
The Quality Standard: Why Finished Product From Thailand Is Impractical Today
Since 1 July 2023, Australia has brought finished medicinal cannabis under equivalent Good Manufacturing Practice (GMP) requirements regardless of where it was manufactured; the quality standard TGO 93 is the reference point for what a finished medicinal cannabis product must meet. For finished product, section 13(3) of TGO 93 accepts country-specific GMP evidence issued by the regulatory authorities of a named set of jurisdictions. That is not a closed list of permitted origins:
| GMP evidence accepted from | Consequence for a Thai producer |
|---|---|
| United Kingdom · European Union member states · Canada · South Africa · Israel · New Zealand (named in TGO 93 s 13(3); position as at July 2026, verify current jurisdictions with the TGA) | Finished product from these origins can rely on GMP evidence issued by the named authority. |
| Any other country, including Thailand (TGO 93 s 13(3)(f)) | Not excluded. Product manufactured in any other country can still meet the standard on written confirmation from the TGA that the manufacturing site operates in accordance with the PIC/S Guide to GMP, a facility inspection the sponsor pays for. A real pathway, but a slow and costly one, which is why finished-product export from Thailand is not the practical route today. |
Read plainly: a GACP farm in Thailand cannot ship patient-ready, finished medicinal cannabis into Australia on the strength of its Thai certification alone. The finished-product route runs through a TGA facility inspection that the sponsor pays for, so that door is closed in practice rather than in law. The other one is genuinely open.
The Door That Is Open: Starting Material
The TGA allows starting materials, including active pharmaceutical ingredients, to be imported without those goods being entered in the ARTG, as long as they are not in a form that can be given to a patient. Bulk cannabis flower destined for further manufacture is a starting material, not a finished medicine.
Alongside this, the TGA treats early cultivation-stage steps as GMP-exempt. A cultivation site may grow, cut and dry cannabis plant material, or perform the first crude extraction step, without itself holding a GMP licence, provided the material then goes to further manufacture at a GMP-approved site, and that GMP site may be located overseas. The GMP obligation attaches to the manufacturer downstream, not to the farm that grows and dries the flower.
One border control the ARTG exemption does not remove. Cannabis is a border-controlled narcotic. Bringing it into Australia, even as a starting material, even ARTG-exempt, still requires the Australian importer to hold an ODC licence to import and a per-consignment import permit under the narcotic import controls. ARTG exemption removes the product-registration requirement; it does not remove the import-licensing gate. That licence and permit are held by your Australian counterparty, not by the Thai farm, but they are the step that gates timing, so plan around them early.
There are two clean routes for the flower, and it is worth keeping them separate:
Route A: starting material into an Australian GMP manufacturer
1. The farm grows, dries and cures flower to GACP standards and documents each batch: the cultivation-stage work that is GMP-exempt.
2. The flower is imported into Australia as a starting material (not patient-ready), under the importer’s ODC import licence and permit.
3. A TGA-licensed Australian GMP manufacturer performs the manufacturing steps and takes on GMP responsibility for the finished product.
4. The finished product reaches Australian patients under an approved access pathway (below), under the sponsor’s control.
Route B: overseas GMP, then finished product into Australia
1. The farm supplies the same GACP flower to a GMP-approved site in an accepted-origin country (per the list above).
2. That site manufactures and releases the finished product under its own GMP.
3. The finished product is then imported into Australia under the accepted-origin finished-product rules: the EU-style chain, landing at the same patient pathways.
Either way, the farm’s job is narrow and clear: supply consistent, audit-ready GACP flower with complete batch documentation, so the downstream GMP manufacturer can build on it without rework. It is the same division of labour that already carries Thai GACP flower into the EU: the farm supplies audited flower and documentation, and a licensed EU-GMP processor in the destination market performs release. Australia simply names different pathways at the patient end.
The Third Regulator: Biosecurity
Most write-ups of the Australian route stop at the medicines regulator and the narcotics office. There is a third gate, and it is the one that most often surprises a first-time supplier: biosecurity.
Cannabis plant material entering Australia is also regulated by the Department of Agriculture, Fisheries and Forestry through its BICON import-conditions database. The relevant case, “Hemp seed and hemp products (Cannabis spp.)”, states on its face that it covers hemp seed and hemp products imported as medicinal cannabis products, so a starting-material consignment is assessed there as well as by the TGA and the Office of Drug Control.
Two features of that case matter commercially. First, the conditions branch: what applies to a consignment depends on the form of the material, whether it is in retail packaging, what treatment it has received and whether manufacturing details are assessed, and the branches carry different documentation and inspection outcomes. Bulk starting material is not retail packaged in the sense the case uses that term, because it still requires further processing before supply, so concessions written for retail-packaged goods should not be assumed to apply to it. Second, several conditions attach at origin rather than on arrival, which puts treatment, documentation and sequencing on the exporter’s side of the transaction. A supplier that discovers this late loses weeks.
Import conditions are revised regularly. As at 4 August 2026 the case was last revised effective 30 July 2026 and carries active alerts and a change notice, so the operative branch conditions should be confirmed in BICON for the specific consignment, and reflected in the supply agreement, before contracting. We plan treatment and documentation into the harvest and shipping schedule rather than after it.
The Patient End: How Unapproved Product Is Supplied
Once a finished, unapproved product exists, it reaches Australian patients principally through the Special Access Scheme Category B (SAS-B), the Authorised Prescriber scheme, or a clinical trial, with SAS Category A also available for seriously ill patients. Throughout, the product is held under the sponsor’s direct control. This is the demand structure a Thai supplier is ultimately feeding, several steps downstream.
Australia Route-to-Market at a Glance
| Element | Status for a Thai GACP farm | Who holds it |
|---|---|---|
| Finished-product wholesale of unapproved cannabis | Not available | Prohibited for unapped finished product; must stay under sponsor’s direct control |
| Thai-manufactured finished product on GMP proof alone | Not accepted | Thailand is not among the named jurisdictions, TGA facility inspection required under s 13(3)(f) |
| Bulk flower as a starting material | Available | Importable without ARTG entry (not patient-ready), but still needs the importer’s ODC import licence + permit |
| Wholesale of starting material | Permitted, conditional | Allowed to a storage facility → TGA-licensed / accepted-origin GMP site; not direct to unlicensed pharmacy |
| Cultivation, drying, first crude extraction | GMP-exempt | The farm, provided material goes to a GMP site (which may be overseas) |
| GMP manufacture of the finished product | Downstream | A GMP-licensed manufacturer (AU or accepted origin) |
| Supply to the patient | Pathway-gated | Sponsor, via SAS-B / Authorised Prescriber / clinical trial (SAS-A for seriously ill) |
What the Australian Buyer Actually Needs From the Farm
Because the GMP burden sits downstream, an Australian sponsor or a GMP manufacturer sourcing Thai flower is really vetting the input. The questions they ask a farm are the questions a GACP-certified supplier in Thailand should already be able to answer on paper:
Starting-material vetting checklist:
1. Thai GACP certification (DTAM) plus GACP compliance evidenced by an independent third-party audit, so the input meets a recognised cultivation standard.
2. A per-batch certificate of analysis: cannabinoid assay, microbial quality, heavy metals and pesticides: the data a downstream GMP manufacturer needs for release testing.
3. Documented, on-site drying and curing under GACP SOPs: post-harvest steps done and recorded at origin, not patched later.
4. Batch and cultivation records tracing each lot to its room, cycle and inputs, so the finished-product manufacturer can maintain traceability.
5. A valid Thai export licence under the Ministerial Regulation on Licensing for Research, Export, Commercial Distribution or Processing of Controlled Herbs (No. 2) B.E. 2569 (2026), in force since 30 April 2026; see our Thailand Cannabis and Hemp Act 2026 tracker for the licensing changes affecting any Thai supplier, including the status of the pending Cannabis and Hemp Control Act.
What Stays True for GACP-Certified Supply
Every requirement the starting-material route places on the farm is a subset of what dual certification already demands: recognised cultivation standard, documented post-harvest handling, per-batch testing, traceability. Solar Farm holds Thai GACP certification (DTAM) and compliance with the EMA GACP guideline, is commissioning in-house HPLC potency testing, and ships an independent third-party certificate of analysis on every batch, and operates 22 flowering rooms across 5,800 m² of indoor facility whose SOPs, from air-locks to visitor management, you can inspect in our room-by-room compliance walkthrough. Because cultivation is fully indoor, batches are consistent year-round rather than seasonal, which is exactly what a downstream GMP manufacturer wants from a starting material.
Regulatory Watch: What Could Change
Where the route stands. Australia imported cannabis from 16 countries in 2024. Canada supplied 80 per cent of the volume, 62,111 kg. Thailand supplied 1,093 kg, up from 11 kg the year before, the largest proportional increase of any origin country. The base is small and the trajectory is real, which is roughly where the Thailand to Australia route sits today. Australia’s Office of Drug Control does not publish 2025 country data until the third quarter of 2026. (Office of Drug Control import data, as analysed by StratCann, October 2025.)
Australia’s medicinal cannabis access framework is under active review. In its consultation response published on 20 February 2026 (786 submissions) the TGA reported agreement across stakeholder groups that the current access framework for unapproved medicinal cannabis is “not fit-for-purpose and not proportionate to the potential safety and quality risks”, and the Office of Drug Control has consulted on revised permit-holder supply pathways. The starting-material and access mechanics described here are current as of this update, but the patient-end pathways in particular may shift, and the accepted-origin list and import controls are administered by the TGA and ODC and can change. We date-stamp this page and log changes below; confirm the live position with the TGA and ODC before contracting.
How Licensed Buyers Start
- Enquire with your licence details. We work with licensed businesses only: Australian sponsors, GMP manufacturers and their sourcing partners. We verify counterparties first.
- Receive the starting-material dossier. Certifications, audit summary, sample COAs and batch-record structure: everything the vetting checklist above asks for.
- Audit us. Remote document audit or an on-site visit under our visitor-management SOP; your GMP manufacturer is welcome in the room.
- Align documentation to your manufacturer and permits. Batch, quantity and specification matched to your GMP site’s release requirements, your Thai export authorisation, and your ODC import licence and permit timing.
Ready to evaluate Thai GACP flower as a starting material for your Australian supply chain? Contact our export team for the starting-material dossier.
Changelog
August 4, 2026: Correction. The TGO 93 accepted-origin list is not a closed list. Under section 13(3)(f), product manufactured in any other country, including Thailand, may meet the standard on written TGA confirmation of PIC/S GMP compliance, so the comparison table, the surrounding text and the section heading were corrected to describe a practical constraint rather than a legal exclusion. The February 2026 TGA consultation response was re-attributed to stakeholder submissions and quoted accurately, and the Thai export-licence reference now names the operative Ministerial Regulation. Same day: a biosecurity section and matching FAQ were added covering the Department of Agriculture, Fisheries and Forestry BICON import-conditions case (last revised effective 30 July 2026), a 2024 origin-volume paragraph was added to Regulatory Watch, and the GMP-scope answer was tightened to state that the section 13 exemption stops at the cultivation stage.
July 20, 2026 · Page published: TGO 93 finished-product quality standard and the accepted-origin GMP list; starting-material and cultivation-stage GMP exemptions; the ODC import-licence/permit gate; the scoped wholesale rule (finished product prohibited, starting material permitted conditionally); Routes A (Australian GMP) and B (overseas accepted-origin GMP); SAS-B / Authorised Prescriber / clinical-trial pathways; note on the 2026 access-framework review.
Frequently Asked Questions
Can a Thai GACP farm export medical cannabis to Australia?
Not as finished, patient-ready product on the strength of Thai certification: Thailand is not among the jurisdictions whose GMP evidence the TGA accepts, so Thai-manufactured finished product would need a TGA GMP inspection. It can, however, supply bulk flower into Australia’s chain as a starting material for downstream GMP manufacture, which is the practical route today.
Is starting-material import into Australia just an ARTG question?
No. ARTG exemption means bulk flower does not need product registration because it is not patient-ready. But cannabis is a border-controlled narcotic, so importing it still requires the Australian importer to hold an ODC licence to import and a per-consignment import permit under the narcotic import controls. The registration exemption does not remove the import-licensing gate.
Does a Thai farm need its own GMP licence to supply Australia?
No, not for the cultivation stage. Under section 13(1) of TGO 93 the overseas-GMP requirement does not apply to plant material used as starting material in the manufacture of another medicinal cannabis product, where that manufacture happens under an Australian Part 3-3 licence or at an overseas site meeting sections 13(2) and 13(3). In practice a cultivator may grow, cut and dry the material, or perform the first crude extraction, without holding GMP itself. Every step after that, including decontamination, storage, testing, packaging, labelling and release for supply, is a GMP step, and the site storing bulk dried flower needs a licence. The exemption is from section 13 only: section 6(1)(b) applies the rest of TGO 93 to the cannabis plant as an ingredient, so contaminant limits and identification testing still apply to every batch, and the Australian manufacturer must qualify the grower as a supplier under PIC/S GMP Annex 7. A cultivator’s certificate of analysis supports that qualification, it does not replace release testing, which is the Australian licensee’s responsibility.
Can cannabis be wholesaled in Australia?
It depends what is being wholesaled. Finished, unapproved medicinal cannabis cannot be supplied through wholesale arrangements, even to or by a state or territory licensed wholesaler, and must stay under the sponsor’s direct control until supplied to a patient through an approved pathway. But that direct-control rule does not apply to starting materials such as bulk dried flower, which can be supplied via wholesale, subject to the condition that material without accepted GMP evidence moves only to a storage facility and on to a TGA-licensed manufacturing site, not directly to an unlicensed pharmacy. The small number of ARTG-registered cannabis medicines can be wholesaled in the ordinary way.
What documentation does an Australian buyer need from a Thai starting-material supplier?
Thai GACP certification (DTAM) with GACP compliance evidenced by independent third-party audit; a per-batch certificate of analysis covering cannabinoid assay, microbials, heavy metals and pesticides; documented on-site drying and curing under GACP SOPs; batch and cultivation records tracing each lot to room, cycle and inputs; and a valid Thai export licence under the Ministerial Regulation on Licensing for Research, Export, Commercial Distribution or Processing of Controlled Herbs (No. 2) B.E. 2569 (2026), in force since 30 April 2026.
Is the Australian pathway going to change?
Possibly. In its consultation response of 20 February 2026 the TGA reported agreement across stakeholder groups that the current access framework for unapproved medicinal cannabis is “not fit-for-purpose and not proportionate to the potential safety and quality risks”, and the Office of Drug Control has consulted on revised supply pathways. The starting-material import mechanics are stable, but the patient-end access pathways may shift. Confirm the current position with the TGA and ODC before contracting; we update this page and log changes when the framework moves.
Does a Thai consignment need biosecurity clearance as well as TGA and ODC approval?
Yes. Cannabis plant material is also assessed by the Department of Agriculture, Fisheries and Forestry under its BICON import conditions, and the relevant case covers hemp products imported as medicinal cannabis products. The conditions branch by the form of the material, whether it is in retail packaging, what treatment it has received and whether manufacturing details are assessed. Several of those conditions attach at origin rather than on arrival, so they have to be planned into the harvest and shipping schedule and documented in the consignment paperwork. BICON conditions are revised regularly, and the case was last revised effective 30 July 2026, so confirm the current branch for your consignment before contracting.